ADC Therapeutics SA (ADCT) vs Humacyte, Inc. (HUMA)
ADC Therapeutics SA and Humacyte, Inc. are both Biotechnology companies. ADC Therapeutics SA and Humacyte, Inc. are of similar size ($166.7M and $164.7M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against 3.03%. ADC Therapeutics SA has the higher net margin (−121.8% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 16 metrics below, ADC Therapeutics SA leads on 12 and Humacyte, Inc. on 4.
Valuation
Profitability
| Metric | ADCT | HUMA | Biotechnology median |
|---|---|---|---|
| Gross margin | 88.86% | (494.58%) | 65.16% |
| Operating margin | (125.08%) | (5,240.78%) | 0.00% |
| Net margin | (121.77%) | (4,448.89%) | 0.00% |
| Free cash flow margin | (127.72%) | (4,599.72%) | 0.00% |
| Return on equity | 45.35% | (534.42%) | (57.72%) |
| Return on assets | (32.25%) | (68.16%) | (49.22%) |
| Return on invested capital | 0.00% | (433.66%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack